Royal Marsden Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (20)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

    Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60

2021

  1. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

    The Lancet Haematology, Vol. 8, Núm. 12, pp. e934-e946

  2. Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial

    ESMO Open, Vol. 6, Núm. 2

2018

  1. Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe

    Journal of Molecular Diagnostics, Vol. 20, Núm. 4, pp. 483-494

2017

  1. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis

    European Journal of Haematology, Vol. 99, Núm. 3, pp. 199-206

  2. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2016

  1. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer

    Gynecologic Oncology, Vol. 142, Núm. 1, pp. 62-69

  2. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): A randomised, double-blind, placebo-controlled phase 3 trial

    The Lancet, Vol. 387, Núm. 10023, pp. 1066-1074

  3. European society of gynaecologic oncology quality indicators for advanced ovarian cancer surgery

    International Journal of Gynecological Cancer, Vol. 26, Núm. 7, pp. 1354-1363

  4. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

  5. Intraoperative transfusion practices in Europe

    British Journal of Anaesthesia, Vol. 116, Núm. 2, pp. 255-261viii

  6. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma

    Blood, Vol. 128, Núm. 4, pp. 497-503

2014

  1. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

    Journal of Clinical Oncology, Vol. 32, Núm. 6, pp. 587-600

  2. Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer)

    European Journal of Cancer

2013

  1. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

    European Journal of Cancer, Vol. 49, Núm. 18, pp. 3831-3838

2012

  1. Mortality after surgery in Europe: A 7 day cohort study

    The Lancet, Vol. 380, Núm. 9847, pp. 1059-1065

  2. Variations in non-pharmacological anti-infective measures in childhood leukemia - results of an international survey

    Haematologica, Vol. 97, Núm. 10, pp. 1548-1552

2007

  1. Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology Consortium

    International Journal of Radiation Oncology Biology Physics, Vol. 68, Núm. 1, pp. 13-23

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051